WWW.PHARMAORG.COM WWW.PHARMAORG.COM: Any drug you wish to know about

ALBENZA       

      Albenza is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm. This medicine may also be used for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm.

How Taken
Albenza should be taken with food.

Warnings/Precautions
Albenza may cause fetal harm, therefore, you should begin treatment after a negative pregnancy test. During therapy, because of the possibility of harm to the liver or bone marrow, routine (every 2 weeks) monitoring of blood counts and liver function tests should take place. Talk to your doctor about possible harm to the fetus if you plan on becoming pregnant while on Albenza or within 1 month of completing treatment.

Missed Dose
If you miss a dose, use it as soon as you remember. If it is near the time of the next dose, skip the missed dose and resume your usual dosing schedule. Do not double the dose to catch up.

Possible Side Effects
The symptoms are usually mild and resolved without treatment.
Searching for something else? No problem!

Search for anything:

Implanted Nerve Stimulator Eases Epilepsy in Kids.
         Stimulation of a cranial nerve through an implant can effectively treat some children with epilepsy, according to the results of a new two-year study. In a study of more than 75 young patients, doctors found that 59 percent of those implanted with a vagus nerve stimulator did not suffer from localization-related epilepsy, or seizures occurring in one part of the brain. Hospital visits for epilepsy-related conditions also decreased by 41 percent, the researchers reported Wednesday at the International League Against Epilepsy Congress in Paris. The nerve stimulator is implanted in the left side of a patient's neck and works by sending signals to the brain to decrease the electrical activity that leads to seizures. It was approved by the U.S. Food and Drug Administration in 1997 for the treatment of epilepsy unresponsive to medication.
Main Page  Site Map